European Leukemia Trial Registry
Trial: B1871039 (BYOND)

More Details
Title A Phase 4 Safety and Efficacy Study of Bosutinib in patients with CML
Scientific Title A Phase 4 Safety and Efficacy Study of Bosutinib in Patients with Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated with One or More Tyrosine Kinase Inhibitors
Short Title B1871039 (BYOND)
Trialgroup NN
Type of Trial open-label
Disease Chronic myeloid leukemia(CML) Intolerant/resistant to one TKI
Age >= 18 years
Status No longer recruiting
Start of Recruitment 01.01.2015
Leader Hochhaus, Prof. Dr. med., Andreas
Shortprotocol Shortprotocol
created 02.04.2015 Hanna Ebert
changed 19.09.2017 Student Studienregister
ELIC European Leukemia Information Center | no responsibility is taken for correctness and completeness of this information | www.leukemia-net.org | elic@leukemia-net.org